Journal Home
Search for

Volume 91, Issue 3, Pages 687-693 (March 2009)


View previous. 9 of 92 View next.

Expression of interleukin-8 and monocyte chemotactic protein 1 in women with endometriosis

Murat Ulukus, M.D.a, E. Cagnur Ulukus, M.D.b, Ege N. Tavmergen Goker, M.D.ac, Erol Tavmergen, M.D.ac, Wenxin Zheng, M.D.d, Aydin Arici, M.D.eCorresponding Author Informationemail address

Received 2 November 2006; received in revised form 27 December 2007; accepted 27 December 2007. published online 04 March 2008.

Objective

To investigate the expression and localization of interleukin-8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) in women with and without endometriosis.

Design

Comparative immunohistochemical study.

Setting

Academic medical center.

Patient(s)

Ectopic (n = 24) and homologous eutopic endometrium (n = 24) from women with endometriosis and endometrium from women without endometriosis (n = 27) were used for immunohistochemical analysis of IL-8 and MCP-1.

Intervention(s)

Tissue sections were immunostained with antihuman IL-8 and MCP-1 antibodies.

Main Outcome Measure(s)

Microscopic evaluation to assess the presence and localization of IL-8 and MCP-1 throughout the menstrual cycle in both eutopic endometrial and endometriotic tissues of women with endometriosis and comparison with normal endometrium.

Result(s)

In normal endometrium, secretory phase samples expressed higher levels of epithelial IL-8 than in proliferative phase samples. Epithelial MCP-1 expression was similar in both proliferative and secretory phases. Proliferative phase samples showed higher epithelial IL-8 and MCP-1 expressions in eutopic endometrium of women with endometriosis compared with that of normal women. Immunoreactivities of both chemokines were significantly increased in the epithelial cells of ectopic endometrial tissues compared with those of normal endometrium.

Conclusion(s)

These findings suggest that IL-8 and MCP-1 may be involved in the pathogenesis of endometriosis.

a Department of Obstetrics & Gynecology, Ege University School of Medicine, Bornova, Izmir, Turkey

b Department of Pathology, Dokuz Eylul University School of Medicine, Inciralti, Izmir, Turkey

c Ege University Family Planing and Infertility Research and Treatment Center, Bornova, Izmir, Turkey

d Department of Pathology, Yale University School of Medicine, New Haven, Connecticut

e Department of Obstetrics and Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut

Corresponding Author InformationReprint requests: Aydin Arici, M.D., Section of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT, 06520-8063 (FAX: 203-785-7134).

 M.U. has nothing to disclose. E.C.U. has nothing to disclose. E.N.T.G. has nothing to disclose. E.T. has nothing to disclose. W.Z. has nothing to disclose. A.A. has nothing to disclose.

 Supported by a Turkish Scientific and Technical Research Institution (TUBITAK) training award to Murat Ulukus.

 Wenxin Zheng's present address is Department of Pathology, University of Arizona, Tucson, AZ 85724.

PII: S0015-0282(07)04376-2

doi:10.1016/j.fertnstert.2007.12.067


View previous. 9 of 92 View next.